Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2005.060038v1, 2005; 10.1373/clinchem.2005.060038
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.060038v1
52/1/112    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Bergmann, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Bergmann, A.

Received on September 2, 2005
Accepted on October 10, 2005

Endocrinology and Metabolism

Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin

Nils G. Morgenthaler 1*, Joachim Struck 1, Christine Alonso 1, Andreas Bergmann 1

1 Research Department, B.R.A.H.M.S AG, Biotechnology Centre Hennigsdorf/Berlin, Germany

* To whom correspondence should be addressed. E-mail: n.morgenthaler{at}brahms.de.

Background: Arginine vasopressin (AVP) is a key regulator of water balance, but its instability makes reliable measurement difficult and precludes routine use. We present a method for quantifying AVP release by use of copeptin, a glycopeptide comprising the C-terminal part of the AVP prohormone.

Methods: We measured copeptin in 50-µL serum and plasma samples from healthy individuals and from critically ill patients with sepsis. Our sandwich immunoluminometric assay used 2 polyclonal antibodies to amino acids 132-164 of pre-provasopressin.

Results: The assay yielded results within 3 h. The analytical detection limit was 1.7 pmol/L, and the interlaboratory CV was <20% for values >2.25 pmol/L. The assay was linear on dilution of the analyte. Ex vivo copeptin stability (<20% loss of analyte) for at least 7 days at room temperature and 14 days at 4 °C was shown for serum and EDTA-, heparin-, and citrate plasma. Copeptin (median, 4.2 pmol/L; range, 1-3.8 pmol/L) was detectable in 97.5% of 359 healthy individuals and was not associated with age. Median concentrations were considerably higher in men than women, increased significantly after exercise, and were influenced by fasting and water load. Copeptin was significantly (P <0.001) increased in 60 critically ill patients with sepsis (median, 79.5 pmol/L; range, 10.6-228.0 pmol/L). The correlation between copeptin and AVP for 110 samples was r = 0.78 (P <0.0001).

Conclusions: Copeptin is stable for days after blood withdrawal and can be quickly and easily measured. The copeptin assay may be a useful alternative to direct measurement of AVP concentration.


The following articles in journals at HighWire Press have cited this article:


Home page
 Diabetes CareHome page
C. Maier, M. Clodi, S. Neuhold, M. Resl, M. Elhenicky, R. Prager, D. Moertl, G. Strunk, A. Luger, J. Struck, et al.
Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 Diabetes
Diabetes Care, October 1, 2009; 32(10): 1890 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
U. Saleem, M. Khaleghi, N. G. Morgenthaler, A. Bergmann, J. Struck, T. H. Mosley Jr., and I. J. Kullo
Plasma Carboxy-Terminal Provasopressin (Copeptin): A Novel Marker of Insulin Resistance and Metabolic Syndrome
J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2558 - 2564.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Reichlin, W. Hochholzer, C. Stelzig, K. Laule, H. Freidank, N. G. Morgenthaler, A. Bergmann, M. Potocki, M. Noveanu, T. Breidthardt, et al.
Incremental value of copeptin for rapid rule out of acute myocardial infarction.
J. Am. Coll. Cardiol., June 30, 2009; 54(1): 60 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. A. Voors, S. von Haehling, S. D. Anker, H. L. Hillege, J. Struck, O. Hartmann, A. Bergmann, I. Squire, D. J. van Veldhuisen, K. Dickstein, et al.
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study
Eur. Heart J., May 2, 2009; 30(10): 1187 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Fenske, S. Stork, A. Blechschmidt, S. G. K. Maier, N. G. Morgenthaler, and B. Allolio
Copeptin in the Differential Diagnosis of Hyponatremia
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 123 - 129.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, N. G. Morgenthaler, A. Bergmann, D. Moertl, R. Berger, and R. Pacher
Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Prediction of Death at Different Stages of the Disease
J. Am. Coll. Cardiol., July 22, 2008; 52(4): 266 - 272.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, T. Breidthardt, M. Christ-Crain, R. Bingisser, D. Miedinger, J. Leuppi, B. Mueller, M. Tamm, and C. Mueller
Use of B-Type Natriuretic Peptide in the Risk Stratification of Acute Exacerbations of COPD
Chest, May 1, 2008; 133(5): 1088 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez
Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia
Clin. Chem., December 1, 2007; 53(12): 2193 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Szinnai, N. G. Morgenthaler, K. Berneis, J. Struck, B. Muller, U. Keller, and M. Christ-Crain
Changes in Plasma Copeptin, the C-Terminal Portion of Arginine Vasopressin during Water Deprivation and Excess in Healthy Subjects
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3973 - 3978.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Katan, N. G. Morgenthaler, K. C. S. Dixit, J. Rutishauser, G. E. Brabant, B. Muller, and M. Christ-Crain
Anterior and Posterior Pituitary Function Testing with Simultaneous Insulin Tolerance Test and a Novel Copeptin Assay
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2640 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm
Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD
Chest, April 1, 2007; 131(4): 1058 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Jochberger, N. G. Morgenthaler, V. D. Mayr, G. Luckner, V. Wenzel, H. Ulmer, S. Schwarz, W. R. Hasibeder, B. E. Friesenecker, and M. W. Dunser
Copeptin and Arginine Vasopressin Concentrations in Critically Ill Patients
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4381 - 4386.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
V. Borisenko, W. Hu, P. Tam, I. Chen, J.-F. Houle, and W. Ausserer
Diffractive optics technology: a novel detection technology for immunoassays.
Clin. Chem., November 1, 2006; 52(11): 2168 - 2172.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Papassotiriou, N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann
Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma
Clin. Chem., June 1, 2006; 52(6): 1144 - 1151.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.